Table 5.
Adjusted absolute efficacy for biologic DMARDS + MTX at 24/26 and 48/54 weeks
| Treatments relative to effect | Absolute HAQ CFB at 24/26 weeks (95% CrL)* |
Absolute HAQ CFB at 48/54 weeks (95% CrL)** |
Proportion (%) of patients with ACR-50 at 24/26 weeks (95% CrL) * |
Proportion (%) of patients with ACR-50 at 48/54 weeks (95% CrL)** |
Proportion (%) of patients with DAS28 < 2.6 at 24/26 weeks (95% CrL)* |
Proportion (%) of patients with DAS28 < 2.6 at 48/54 weeks (95% CrL)* |
|---|---|---|---|---|---|---|
| Placebo + MTX | -0.29 (-0.31; -0.26) |
-0.29 (-0.34; -0.24) |
11.9% (9.7%; 14.0%) |
12.5% (9.4%; 15.5%) |
2.6% (1.4%; 4.1%) |
7.0% (4.7%; 9.8%) |
| Adalimumab + MTX | -0.61 (-0.77; -0.46) |
-0.63 (-0.74; -0.51) |
53.5% (28.0%; 77.9%) |
49.5% (35.9%; 63.5%) |
||
| Certolizumab Pegol + MTX | -0.67 (-0.82; -0.53) |
-0.71 (-0.81; -0.61) |
57.3% (31.2%; 79.9%) |
51.7% (38.1%; 66.1%) |
33.4% (4.4%; 90.0%) |
|
| Etanercept + MTX | -0.56 (-0.75; -0.38) |
-0.63 (-0.87; -0.39) |
30.7% (15.6%; 65.2%) |
43.2% (31.8%; 54.9%) |
6.9% (1.0; 31.5%) |
18.7% (1.8%; 73.3%) |
| Golimumab + MTX | -0.63 (-0.86; -0.39) |
34.6% (9.7%; 69.2%) |
9.6% (1.4%; 42.4%) |
|||
| Infliximab + MTX | -0.48 (-0.62; -0.33) |
-0.48 (-0.59; -0.36) |
26.0% (6.6%; 57.4%) |
28.1% (19.4%; 38.3%) |
12.6% (1.9%; 53.3%) |
28.8% (1.9%; 89.5%) |
| Rituximab + MTX | -0.49 (-0.68; -0.31) |
-0.59 (-0.91; -0.27) |
35.3% (14.8%; 61.9%) |
64.1% (32.4%; 91.3%) |
||
| Tocilizumab + MTX | -0.49 (-0.73; -0.26) |
47.5% (16.1%; 78.6%) |
71.0% (19.0%; 98.9%) |
|||
| Abatacept + MTX | -0.58 (-0.70; -0.46) |
-0.58 (-0.66; -0.50) |
31.7% (15.9%; 50.6%) |
35.4% (27.3%; 43.3%) |
11.3% (3.7%; 28.8%) |
40.2% (10.4%; 80.3%) |
Note: For HAQ CFB, negative values indicate improvement.
* Results based on a random effects model. ** Results based on a fixed effects model.
95% CrL, 95% credible limits